Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: Secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008

Critical Care

Volumn 14, Issue 3, 2010, Pages

  Meyer, Elisabeth ^a,b   Schwab, Frank ^a,b   Schroeren Boersch, Barbara ^c   Gastmeier, Petra ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b National Reference Centre for Surveillance of Nosocomial Infections   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CARBAPENEM; CARBAPENEMASE; CEPHALOSPORIN; IMIPENEM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; DENSITY; DRUG USE; ESCHERICHIA COLI; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LABORATORY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS; BACTEREMIA; CLINICAL PRACTICE; DRUG EFFECT; GERMANY; HEALTH SURVEY; STATISTICS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; GERMANY; HUMANS; INTENSIVE CARE UNITS; PHYSICIAN'S PRACTICE PATTERNS; POPULATION SURVEILLANCE;

EID: 77953342816     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9062     Document Type: Article

References (40)

1. WHO Global Strategy for Containment of Antimicrobial Resistance. , http://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf
2. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003, 36:S11-S23. 10.1086/344654, 12516026.
3. Foster KR, Grundmann H. Do we need to put society first? The potential for tragedy in antimicrobial resistance. PLoS Med 2006, 3:e29. 10.1371/journal.pmed.0030029, 1325265,1325265, 16398572.
4. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008, 6:751-763. 10.1586/14787210.6.5.751, 18847410.
5. Bronzwaer SL, Cars O, Buchholz U, Molstad S, Goettsch W, Veldhuijzen IK, Kool JL, Sprenger MJ, Degener JE. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002, 8:278-282. 10.3201/eid0803.010192, 2732471, 11927025.
6. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004, 3:14. 509280, 15283864, 10.1186/1476-0711-3-14.
7. Molstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G, Lundborg CS, Soderstrom A, Torell E, Cars O. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis 2008, 8:125-132. 10.1016/S1473-3099(08)70017-3, 18222163.
8. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. Hospital consumption of antibiotics in 15 European countries: results of the ESAC Retrospective Data Collection (1997-2002). J Antimicrob Chemother 2006, 58:159-167. 10.1093/jac/dkl147, 16698845.
9. Meyer E, Gastmeier P, Schwab F. The burden of multiresistant bacteria in German intensive care units. J Antimicrob Chemother 2008, 62:1474-1476. 10.1093/jac/dkn391, 18794158.
10. Meyer E, Jonas D, Schwab F, Rueden H, Gastmeier P, Daschner FD. Design of a surveillance system of antibiotic use and bacterial resistance in German intensive Care units (SARI). Infection 2003, 31:208-215.
11. Meyer E, Schwab F, Gastmeier P, Jonas D, Rueden H, Daschner FD. Methicillin-resistant Staphylococcus aureus in German intensive care units during 2000-2003: data from project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in Intensive Care Units). Infect Control Hosp Epidemiol 2006, 27:146-154. 10.1086/500619, 16465631.
12. Surveillance der Antibiotika-Anwendung und der bakteriellen Resistenzen auf Intensivstationen. , http://www.nrz-hygiene.de/sari/sari.htm
13. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index. , http://www.whocc.no/atc_ddd_index/
14. Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). , http://www.rki.de/cln_169/nn_205212/DE/Content/GBE/EpidemiologischeMethoden/Empfehlungen/empfehlungen__pdf1,templateId=raw,property=publicationFile.pdf/empfehlungen_pdf1.pdf
15. Gesetz zur Verhütung und Bekämpfung von Infektionskrankheiten beim Menschen. , http://bundesrecht.juris.de/ifsg/__23.html
16. Meyer E, Buttler J, Schneider C, Strehl E, Schroeren-Boersch B, Gastmeier P, Ruden H, Zentner J, Daschner FD, Schwab F. Modified guidelines impact on antibiotic use and costs: duration of treatment for pneumonia in a neurosurgical ICU is reduced. J Antimicrob Chemother 2007, 59:1148-1154. 10.1093/jac/dkm088, 17434880.
17. Meyer E, Lapatschek M, Bechtold A, Schwarzkopf G, Gastmeier P, Schwab F. Impact of restriction of third generation cephalosporins on the burden of third generation cephalosporin resistant K. pneumoniae and E. coli in an ICU. Intensive Care Med 2009, 35:862-870. 10.1007/s00134-008-1355-6, 19034426.
18. Meyer E, Schwab F, Pollitt A, Bettolo W, Schroeren-Boersch B, Trautmann M. Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit. Infection 2010, 38:19-24. 10.1007/s15010-009-9115-2, 19904488.
19. Hanberger H, Arman D, Gill H, Jindrak V, Kalenic S, Kurcz A, Licker M, Naaber P, Scicluna EA, Vanis V, Hanberger H, Arman D, Gill H, Jindrak V, Kalenic S, Kurcz A, Licker M, Naaber P, Scicluna EA, Vanis V, Walther SM. Surveillance of microbial resistance in European Intensive Care Units: a first report from the Care-ICU programme for improved infection control. Intensive Care Med 2009, 35:91-100. 10.1007/s00134-008-1237-y, 18670757.
20. Erlandsson M, Burman LG, Cars O, Gill H, Nilsson LE, Walther SM, Hanberger H. Prescription of antibiotic agents in Swedish intensive care units is empiric and precise. Scand J Infect Dis 2007, 39:63-69. 10.1080/00365540600740504, 17366015.
21. Hanberger H, Burman LG, Cars O, Erlandsson M, Gill H, Nilsson LE, Nordlinder D, Walther SM. Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period. Acta Anaesthesiol Scand 2007, 51:937-941. 10.1111/j.1399-6576.2007.01364.x, 17635399.
22. European Antimicrobial Resistance Surveillance System annual report 2008. , http://www.rivm.nl/earss/Images/EARSS%202008_final_tcm61-65020.pdf
23. Harris AD, McGregor JC, Johnson JA, Strauss SM, Moore AC, Standiford HC, Hebden JN, Morris JG. Risk factors for colonization with extended-spectrum β-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 2007, 13:1144-1149. 2828082, 17953083.
24. Meyer E, Serr A, Schneider C, Utzolino S, Kern WV, Scholz R, Dettenkofer M. Should we screen patients for extended-spectrum β-lactamase-producing enterobacteriaceae in intensive care units?. Infect Control Hosp Epidemiol 2009, 30:103-105. 10.1086/592702, 19067603.
25. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, Perez-Cano R, Pascual A. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004, 42:1089-1094. 10.1128/JCM.42.3.1089-1094.2004, 356843, 15004058.
26. Arpin C, Quentin C, Grobost F, Cambau E, Robert J, Dubois V, Coulange L, Andre C. Nationwide survey of extended-spectrum β-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother 2009, 63:1205-1214. 10.1093/jac/dkp108, 19329798.
27. Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, Azap OK, Arpin C, Pascual A, Livermore DM, Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, Azap OK, Arpin C, Pascual A, Livermore DM, Garau J, Carmeli Y. A multinational survey of risk factors for infection with extended-spectrum β-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009, 49:682-690. 10.1086/604713, 19622043.
28. Kaier K, Frank U, Hagist C, Conrad A, Meyer E. The impact of antimicrobial drug consumption and alcohol-based hand rub use on the emergence and spread of extended-spectrum beta-lactamase-producing strains: a time-series analysis. J Antimicrob Chemother 2009, 63:609-614. 10.1093/jac/dkn534, 19151036.
29. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9:228-236. 10.1016/S1473-3099(09)70054-4, 19324295.
30. Kitchel B, Sundin DR, Patel JB. Regional dissemination of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2009, 53:4511-4513. 10.1128/AAC.00784-09, 2764151, 19687250.
31. Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, Fabian D, Farajallah A, Levine J, Thomson KS. Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis 2005, 40:e84-e86. 10.1086/429822, 15844056.
32. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007, 35:S165-S193. 10.1016/j.ajic.2007.10.006, 18068814.
33. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleurop,,ischen Raum. , http://www.p-e-g.org/ag_resistenz/main.htm
34. GERMAP 2008 Antibiotika-Resistenz und -Verbrauch. , http://www.bvl.bund.de/cln_007/DE/08__PresseInfothek/00__doks__downloads/Germap__2008,templateId=raw,property=publicationFile.pdf/Germap_2008.pdf
35. Higgins PG DC, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010, 65:233-238. 10.1093/jac/dkp428, 19996144.
36. de With K, Bestehorn H, Steib-Bauert M, Kern WV. Comparison of defined versus recommended versus prescribed daily doses for measuring hospital antibiotic consumption. Infection 2009, 37:349-352. 10.1007/s15010-008-8138-4, 19277464.
37. Muller A, Monnet DL, Talon D, Henon T, Bertrand X. Discrepancies between prescribed daily doses and WHO defined daily doses of antibacterials at a university hospital. Br J Clin Pharmacol 2006, 61:585-591. 10.1111/j.1365-2125.2006.02605.x, 1885049, 16669851.
38. Livermore DM. Has the era of untreatable infections arrived?. J Antimicrob Chemother 2009, 64(Suppl 1):i29-i36. 10.1093/jac/dkp255, 19675016.
39. Tsakris A, Poulou A, Themeli-Digalaki K, Voulgari E, Pittaras T, Sofianou D, Pournaras S, Petropoulou D. Use of boronic acid disk tests to detect extended-spectrum β-lactamases in KPC carbapenemase-possessing enterobacteriaceae clinical isolates. J Clin Microbiol 2009, 47:3420-3426. 10.1128/JCM.01314-09, 2772593, 19726597.
40. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598. 10.1001/jama.290.19.2588, 14625336.